Nintedanib - CAS 656247-17-5
Catalog number: B0084-262244
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C31H33N5O4
Molecular Weight:
539.62
COA:
Inquire
Targets:
FGFR | VEGFR
Description:
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. It exhibits potential antiangiogenic and antineoplastic activities.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-262244 500 mg $279 In stock
Bulk Inquiry
Publication citing BOC Sciences Products
1. Antibacterial and sterilizing effect of benzylpenicillin in tuberculosis
2. Electrophotographic member, process cartridge and electrophotographic apparatus
3. Study of the chromatographic behavior of selected antipsychotic drugs on RP-TLC based on quantitative structure–retention relationships
4. Assessment of biodegradation of the anionic surfactant sodium lauryl ether sulphate used in two foaming agents for mechanized tunnelling excavation
5. Machine learning models identify molecules active against the Ebola virus in vitro
6. "Resurrecting old β-lactams": the potent inhibitory activity of temocillin against multi-drug resistant Burkholderia spp. isolates from the United States

>> More

Brife Description:
inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
Purity:
>98%
Synonyms:
Vargatef; BIBF-1120; BIBF 1120; Intedanib
Solubility:
Water: 9.66 mg/L
MSDS:
Inquire
Application:
the treatment of idiopathic pulmonary fibrosis
InChIKey:
XZXHXSATPCNXJR-ZIADKAODSA-N
InChI:
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
Canonical SMILES:
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5
1.A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model.
Seger S;Stritt M;Vezzali E;Nayler O;Hess P;Groenen PMA;Stalder AK PLoS One. 2018 Mar 16;13(3):e0193057. doi: 10.1371/journal.pone.0193057. eCollection 2018.
Intratracheal administration of bleomycin induces fibrosis in the lung, which is mainly assessed by histopathological grading that is subjective. Current literature highlights the need of reproducible and quantitative pulmonary fibrosis analysis. If some quantitative studies looked at fibrosis parameters separately, none of them quantitatively assessed both aspects: lung tissue remodeling and collagenization. To ensure reliable quantification, support vector machine learning was used on digitalized images to design a fully automated method that analyzes two important aspects of lung fibrosis: (i) areas having substantial tissue remodeling with appearance of dense fibrotic masses and (ii) collagen deposition. Fibrotic masses were identified on low magnification images and collagen detection was performed at high magnification. To insure a fully automated application the tissue classifier was trained on several independent studies that were performed over a period of four years. The detection method generates two different values that can be used to quantify lung fibrosis development: (i) percent area of fibrotic masses and (ii) percent of alveolar collagen. These two parameters were validated using independent studies from bleomycin- and saline-treated animals.
2.F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
Quintela-Fandino M;Lluch A;Manso L;Calvo I;Cortes J;García-Saenz JA;Gil-Gil M;Martinez-Jánez N;Gonzalez-Martin A;Adrover E;de Andres R;Viñas G;Llombart-Cussac A;Alba E;Guerra J;Bermejo B;Zamora E;Moreno-Anton F;Pernas Simon S;Carrato A;Lopez-Alonso A;Escudero MJ;Campo R;Carrasco E;Palacios J;Mulero F;Colomer R Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.
Purpose:; We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with ;18;F-fluoromisonidazole-positron emission tomography (18F-FMISO-PET); we found that reoxygenation of tumors (or lack of it) during a window-of-opportunity (WoO) treatment with TKIs correlated with the benefit (or lack of it) from TKI-plus-chemotherapy combinations. We studied the predictive role of 18F-FMISO-PET for the TKI nintedanib in the neoadjuvant setting in a phase II WoO randomized trial.;Experimental Design:; Patients were randomized to a 14-day WoO of nintedanib preceded and followed by an 18F-FMISO-PET, followed by nintedanib plus weekly paclitaxel (Arm A) or an 18F-FMISO-PET followed by weekly paclitaxel (Arm B) before surgery. The endpoint was residual cancer burden (RCB). The objective was to detect the patients with no response (RCB-III) on the basis of the baseline or evolutive 18F-FMISO-PET values/changes.;Results:; One-hundred and thirty HER2-negative patients were randomized. Seventeen (27.9%), 34 (55.7%), and 8 (13.1%) patients had an RCB of III, II, and I/0, respectively, in Arm A.
3.Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F;Florio T;Ferraù F;Kara E;Fanciulli G;Faggiano A;Colao A;NIKE Group Endocr Relat Cancer. 2018 Sep;25(9):R453-R466. doi: 10.1530/ERC-17-0531. Epub 2018 May 16.
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies ;in vitro; and ;in vivo; studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related FGFR Products

CAS 219580-11-7 PD173074

PD173074
(CAS: 219580-11-7)

PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell prol...

CAS 1265965-22-7 S-49076

S-49076
(CAS: 1265965-22-7)

This active molecular is a Axl receptor tyrosine kinase inhibitor, Proto oncogene protein c met inhibitor, Type-1, Type-2 and Type-3 fibroblast growth factor re...

CAS 1218779-75-9 Apatinib

Apatinib
(CAS: 1218779-75-9)

Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apa...

CAS 639858-32-5 BMS 605541

BMS 605541
(CAS: 639858-32-5)

BMS 605541 is a potent and ATP-competitive VEGFR-2 inhibitor (IC50 = 23 nM) displaying >10-fold selectivity for VEGFR-2 over VEGFR-1. It exhibits antitumor acti...

CAS 212141-51-0 Vatalanib dihydrochloride

Vatalanib dihydrochloride
(CAS: 212141-51-0)

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4.

CAS 193000-39-4 ZM323881 hydrochloride

ZM323881 hydrochloride
(CAS: 193000-39-4)

Potent and selective inhibitor of VEGFR2 (IC50: 2 nM for VEGFR2 vs >50 mM for VEGFR1 respectively)

CAS 872511-34-7 BGJ-398

BGJ-398
(CAS: 872511-34-7)

BGJ398, also known as NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs...

CAS 656247-18-6 BIBF 1120 esylate

BIBF 1120 esylate
(CAS: 656247-18-6)

Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.

Chemical Structure

CAS 656247-17-5 Nintedanib

Quick Inquiry

Verification code

Featured Items